JAK inhibitor safety compared to traditional systemic immunosuppressive therapies

被引：0
|
作者：
Bunick, Christopher [1 ,2 ]
Daniele, Stefano [3 ]
机构：
[1] Yale Univ, Dept Dermatol, New Haven, CT USA
[2] Yale Univ, Program Translat Biomed, New Haven, CT USA
[3] Yale Sch Med, Med Scientist Training Program, New Haven, CT USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
43852
引用
收藏
页码：AB60 / AB60
页数：1
相关论文
共 50 条
  • [31] Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
    Choi, Wonho
    Ahn, Soo Min
    Kim, Yong Gil
    Lee, Chang-Keun
    Yoo, Bin
    Hong, Seokchan
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3238 - 3239
  • [32] Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
    Kahl, L.
    Patel, J.
    Layton, M.
    Binks, M.
    Hicks, K.
    Leon, G.
    Hachulla, E.
    Machado, D.
    Staumont-Salle, D.
    Dickson, M.
    Condreay, L.
    Schifano, L.
    Zamuner, S.
    van Vollenhoven, R. F.
    LUPUS, 2016, 25 (13) : 1420 - 1430
  • [33] Differential NK-suppressive capacity of the JAK2 inhibitor Pacritinib when compared to the JAK1/2 inhibitor Ruxolitinib
    Wolf, D.
    Rudolph, J.
    Brossart, P.
    Schoenberg, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 26 - 26
  • [34] Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus
    Davis, Laurie S.
    Reimold, Andreas M.
    RHEUMATOLOGY, 2017, 56 : 100 - 113
  • [35] Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies
    Bandelier, Cedric
    Guerne, Pierre-Andre
    Genevay, Stephane
    Finckh, Axel
    Gabay, Cem
    SWISS MEDICAL WEEKLY, 2009, 139 (3-4) : 41 - 46
  • [36] Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies
    Wenzhe Zhao
    Jingying Wang
    Haiqin Zhu
    Meng Pan
    Clinical Reviews in Allergy & Immunology, 2021, 61 : 351 - 362
  • [37] Helios as a Potential Biomarker in Systemic Lupus Erythematosus and New Therapies Based on Immunosuppressive Cells
    Paris-Munoz, Andres
    Leon-Triana, Odelaisy
    Perez-Martinez, Antonio
    Barber, Domingo F.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [38] Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies
    Zhao, Wenzhe
    Wang, Jingying
    Zhu, Haiqin
    Pan, Meng
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2021, 61 (03) : 351 - 362
  • [39] Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
    Richard W. Kim
    Megan Lam
    Katrina Abuabara
    Eric L. Simpson
    Aaron M. Drucker
    American Journal of Clinical Dermatology, 2024, 25 : 179 - 193
  • [40] Psoriasis Treatment in HIV-Positive Patients: A Systematic Review of Systemic Immunosuppressive Therapies
    Nakamura, Mio
    Abrouk, Michael
    Farahnik, Benjamin
    Zhu, Tian Hao
    Bhutani, Tina
    CUTIS, 2018, 101 (01): : 38 - +
12345